NKGen Biotech Announces Acceptance of SNK01 Abstract for Presentation at the 2021 Connective Tissue Oncology Society Annual Meeting

SANTA ANA, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that a Phase I study of SNK01 monotherapy in refractory cancers has been accepted for presentation...

Click to view original post